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Abstract Background: A budesonide/formoterol single inhaler has been developed for convenient treatment of pa-
tients whose asthma is inadequately controlled by inhaled glucocorticosteroids alone.Objectives:To compare long-term
safetyandefficacyof budesonide/formoterolsingleinhalerwithbudesonideplus formoterolvia separateinhalersin adults
withasthma.Methods:Inthisopen, randomized, parallel-group 6-monthextensionconductedina subsetofcentres from
a previous 6-month study, patients (n=321) received two inhalations bid of budesonide/formoterol (SymbicortsTurbu-
halers) 160/4.5 mg delivered dose or corresponding doses of budesonide (Pulmicorts Turbuhalers) plus formoterol
(OxissTurbuhalers) via separate inhalers. Results: Significantly fewer patients receiving budesonide/formoterol single
inhaler withdrew compared with budesonide plus formoterol (9 vs.19%, P=0.008). Incidence and severity of AEs were
lowand similarinbothgroups.No clinicallyimportantdifferencesbetweengroups, orchanges, wereidentifiedinlabora-
tory measurements, vital signs or ECG.Treatments produced similar improvements in lung function, ACQ scores and
Mini AQLQ domains that weremaintained throughout12 months.Conclusions:Budesonide/formoterol in a single inhaler
is as safe and effective in the long-term treatment of asthma as budesonide plus formoterol via separate inhalers.The
lower number of withdrawals with budesonide/formoterol may reflect better adherence to treatment compared with
budesonide plus formoterol.r2003 Publishedby Elsevier Science Ltd.
doi:10.1053/rmed.2003.1504, available online athttp://www.sciencedirect.com
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The addition of inhaled long-acting b2-agonists (such as
formoterol and salmeterol) provides a more e¡ective
means of improving lung function and asthma control
than increasing the dose of inhaled glucocorticosteroids
(IGCS) in patients whose asthma is not adequately con-
trolled (1^4), and is recommended in current interna-
tional treatment guidelines (5). Formoterol is unique
amongst b2-agonists in having both a fast onset of action
(as rapid as salbutamol) (6) and a long duration of e¡ect
(similar to salmeterol) (7).When added to budesonide,
formoterol has been shown to reduce the risk of severe
exacerbations (3,4) and associated treatment costs (8),
as well as improving quality of life (9) comparedwith glu-
cocorticosteroid treatment alone.Correspondence should be addressed to Dr L.Rosenhall.Department
of Respiratory Medicine and Allergology. fax: +46-8-711-7306,
E-mail address: leif.rosenhall@lungall.hs.sll.seA single inhaler containing budesonide and formoterol
(Symbicorts Turbuhalers, AstraZeneca) has recently
been developed.Use of a single inhaler, rather than two
separate inhalers, provides a more convenient means of
obtaining the treatment bene¢ts of both drugs andmay
improve adherence to treatment and reduce costs.
Short-term studies with budesonide/formoterol in a sin-
gle inhaler have shown it to be at least as e¡ective as bu-
desonide plus formoterol via separate inhalers in
improving lung function in patients with asthma (10) and
to provide a greater reduction in the frequency of ex-
acerbations than an increased dose of glucocorticoster-
oids (11,12).
A 6-month studyof asthmapatientswhowere already
using IGCS and b2-agonists, demonstrated no statisti-
cally signi¢cant di¡erences in safety or e⁄cacy between
treatmentwith budesonide/formoterol in a single inhaler
and two separate inhalers of budesonide and formoterol
(13). However, there was a trend towards a lower with-
drawal rate in the budesonide/formoterol single inhaler
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of centres in order to compare the safety (primary ob-
jective) and e⁄cacy (secondary objective) of regular
treatmentwith budesonide/formoterol in a single inhaler
with budesonide plus formoterol from two separate in-
halers over the longer term.This paper reports results
from the full12-month study period.
METHODS
Study design
This was an open, randomized, parallel group study con-
ducted in 29 Swedish centres. Adult patients, who had
participated in theprevious 6-month study in this subset
of centres, received the same treatment for a further 6
months. Patientswere randomized at the ¢rst clinic visit
to receive either:
1. Budesonide/formoterolF single inhaler budesonide/
formoterol (Symbicorts Turbuhalers, AstraZeneca),
two inhalations of 160/4.5mg delivered dose twice
daily, or
2. Budesonide plus formoterol F two separate
inhalers of budesonide (Pulmicorts Turbuhalers,
AstraZeneca), two inhalations of 200mg metered
dose (corresponding to 160mg delivered dose) twice
daily plus formoterol (Oxiss Turbuhalers,
AstraZeneca), two inhalations of 4.5mg delivered
dose twice daily.
Randomization was skewed approximately 2:1 in
favour of the single inhaler treatment. Patients were
assessed initially (at randomization) and thereafter
during clinic visits at 1, 3, 6, 9 and 12 months for both
safety and e⁄cacy. Relief medication (terbutaline or
salbutamol) was permitted throughout the study;
brands and strengths had to remain constant. Patients
gave informed consent for their participation in
the study and extension, which was conducted
with the approval of local independent ethics
committees and in accordance with the Declaration of
Helsinki.
Patients
Patients were included if they were Z18 years of age,
had a diagnosis of asthma of Z6 months’ duration,
their forced expiratory volume in 1s (FEV1) was Z50%
of predicted normal, they were treated with a con-
stant dose of Z400^1200mg IGCS for Z30 days and
they used inhaled short- and/or long-acting b2-agonists
daily.
Patients were excluded from the study if they had ex-
perienced a respiratory infection or had been treated
with oral, parenteral or rectal glucocorticosteroids, leu-
kotriene antagonists, inhaled sodium cromoglycate, in-haled nedocromil sodium, oral b2-agonists, xanthines or
inhaled anticholinergics within 30 days of the ¢rst clinic
visit. Patientswere also excluded if they had a known se-
vere cardiovascular disorder, were currently using b-
blockers (including eye drops) or were current or pre-
vious smokerswith a smokinghistoryofZ10 pack-years.
Women who were pregnant, lactating or actively
planning a pregnancy during the study period were
excluded.
Safety assessments
The occurrence, duration and severity of any adverse
events (AEs) were recorded at each visit. Symptoms of
asthma were recorded as AEs if they were considered
serious (resulting in death, life-threatening, requiring
hospitalization, resulting in persistent or signi¢cant dis-
ability/incapacity, a congenital abnormality or birth de-
fect), or resulted in discontinuation from the study.
However, if symptoms of asthmawhichwereneither ser-
ious nor discontinuations were recorded as AEs, they
were not excluded from the analysis. Routine haematol-
ogy, clinical chemistry, urine analysis and 12-lead ECG
measurements were carried out at enrolment, 3, 6 and
12 months. Morning serum cortisol was measured after
ninemonths.
E⁄cacy andquality of life assessments
At each clinic visit, FEV1 and forced vital capacity (FVC)
weremeasured and linguistically validated translations of
questionnaireswere completed to assess control of asth-
ma (Asthma Control Questionnaire, ACQ) and health-
related quality of life (Mini Asthma Quality of Life Ques-
tionnaire,MiniAQLQ).TheACQ scores severityof symp-
toms on a 7-point scale of asthma control from 0 (well-
controlled) to 6 (poor) (14). The MiniAQLQ contains 15
items in four domains (symptoms, activity limitations,
emotional function and environmental stimuli); items
are scored on a 7-point quality-of-life scale from1 (low)
to 7 (high) (15).
Statisticalmethods
Data from the intention-to-treat population were ana-
lysed. The last observation was carried forward for pa-
tients who did not participate in the extension or who
discontinued for other reasons. Safety data were ana-
lysed using descriptive statistics. FEV1 and FVC change
from baseline and the di¡erence between treatments,
were analysed by multiplicative ANOVA. Change in
ACQ andMiniAQLQ scores frombaseline and the di¡er-
ence between treatments were analysed using an addi-
tive ANOVA.
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Patient demographic and baseline
characteristics
Demographic and baseline characteristics were well
matched between the treatment groups (Table 1). Of
the 321randomized patients, eight (3.7%) in the budeso-
nide/formoterol group and ¢ve (4.9%) in the budesonide
plus formoterolgroup didnotparticipate in the 6-month
extension period. Twenty (9.2%) patients in the budeso-
nide/formoterol group and 20 (19.4%) in the budesonide
plus formoterol group discontinued.
Safety
The incidence and severity of AEs were low and similar
between treatment groups (Table 2). As would be ex-
pected in an asthma population, respiratory system dis-
orders were the most common AE. Serious adverse
events (SAEs) were reported for eight patients (3.7%) in
the budesonide/formoterol group and six patients (5.8%)
in the budesonide plus formoterol group. Only one pa-
tient (in the budesonide plus formoterol group) had an
SAE (unspeci¢ed eye symptoms and headache) consid-
ered possibly to be related to treatment.
The incidence of asthma aggravated recorded as AEs
is summarized inTable 3. The frequency of discontinua-
tions due to asthma deterioration was slightly lower in
thebudesonide/formoterol group than in thebudesonide
plus formoterol group (1.4 vs. 4.9%).The frequency of dis-
continuations due to other AEswas similar inboth treat-
ment groups, 1.8 and 2.9%, respectively. Other reasons
for discontinuations were reported in 2.3% of the bude-
sonide/formoterol group (0.5% lost to follow-up, 1.8%TABLE 1. Patientdemographics, baseline characteristics and dis
B
Number
Male/female
Age, years; mean (range)
Time since diagnosis of asthma, years; mean (range)
Smokinghistory, number (%)
Never
Previous
Occasional
Habitual
Pack-years; mean (range)
Dose of IGCS atentry, mg; mean (range)
FEV1 (l) mean (range)
FEV1 (% pred); mean (range)
FVC (l); mean (range)reasons not given) and 7.8% of the budesonide plus for-
moterol group (1.9% lost to follow-up,1.0% eligibility cri-
teria not ful¢lled, 4.9% reasons not given).
No clinically signi¢cant di¡erences between the treat-
mentgroups, or changes over timewithin the treatment
groups, were identi¢ed for laboratory measurements,
vital signs or ECG.The only laboratory variables or vital
signs for which a statistically signi¢cant di¡erence in
changes from baseline between the budesonide/formo-
terol and budesonide plus formoterol groups was found
were serum glucose (mean change 0.13 vs. 0.38mmol/l,
respectively,P=0.047) and change in diastolic bloodpres-
sure (mean change 0.1 vs. 2.6mmHg, respectively,
P=0.01). These changes were not considered to be clini-
cally important.
Four patients (2.2%) had morning serum cortisol values
below the lower reference limit of 160nmol/l after 9
months of treatment (2.9%, budesonide/formoterol;
1.2%, budesonide plus formoterol). A higher proportion
of patients in the budesonide plus formoterol group had
values above the upper reference limit of 830nmol/l,
compared with the budesonide/formoterol group (9.8
vs. 7.8%); the di¡erencewas not statistically signi¢cant.
E⁄cacy
Signi¢cantly fewer patients withdrew in the budesonide/
formoterol group compared with the budesonide plus
formoterol group (9.2% vs. 19.4%, P=0.008) (Fig. 1, Table
1). After exclusion of patients who did not participate in
the 6-month extension, the number of withdrawals re-
mained signi¢cantly lower in the budesonide/formoterol
group compared with the budesonide plus formoterol
group (5.5% vs.14.6%,P=0.005).Therewereno signi¢cantposition
Treatment
udesonide/formoterol Budesonide plus formoterol
218 103
97/121 50/53
44.0 (18^78) 43.2 (19^78)
17.9 (1^61) 16.2 (1^63)
120 (55.1) 74 (71.9)
72 (33.0) 21 (20.4)
9 (4.1) 2 (1.9)
17 (7.8) 6 (5.8)
4.9 (0^9) 5.4 (0^9)
694.9 (400^1600) 671.1 (400^1200)
2.93 (1.2^5.5) 2.99 (1.5^5.0)
94.3 (52^139) 95.5 (61^139)
3.88 (1.8^6.5) 3.98 (2.0^6.1)
TABLE 2. Incidence of adverse events
Treatment
Budesonide/formoterol Budesonide plus formoterol
Numberof patients 218 103
Number (%) of patientswithZ1AE 190 (87) 84 (82)
Numberof AEs/1000 treatmentdays 6 6
Number (%) of AEs
Severe 51 (10) 19 (10)
Moderate 203 (41) 87 (44)
Mild 245 (49) 93 (47)
Number (%) experiencingan event bypreferred term*
Respiratory infection 119 (55) 47 (46)
Viral infection 25 (11) 8 (8)
Headache 18 (8) 10 (10)
Pharyngitis 18 (8) 6 (6)
Dysphonia 15 (7) 5 (5)
Sinusitis 12 (6) 6 (6)
Rhinitis 14 (6) 3 (3)
Tremor 12 (6) 4 (4)
Bronchitis 8 (4) 6 (6)
Backpain (%) 11 (5) 2 (2)
*The10 most frequently reported adverse events are shown.Therewere no statistically signi¢cantdi¡erences betweenthe
treatmentgroups (all, P40.1)
TABLE 3. Incidence of asthma aggravatedrecorded as an AE
Treatment
Budesonide/formoterol Budesonide plus formoterol
Numberof patients 218 103
Numberof patients (%) recordingaggravated asthma as AE 0 (0) 1 (1)
Numberof patients (%) recordingaggravated asthma as SAE 4 (1.8)* 5 (4.9)
*Allpatientswith asthma aggravated as SAEdiscontinuedexceptfor thevalue shownbyasterisk, whointerruptedtreatment
temporarily
BUDESONIDE/FORMOTEROLSINGLE INHALERINASTHMA 705di¡erences between treatment groups in the time to
¢rst exacerbation (de¢ned as the ¢rst use of oral gluco-
corticosteroids).
Increases in FEV1 of 4^6% from baseline (geometric
mean values), occurred with both treatments and were
maintained throughout the study (Fig. 2). Small increases
in FVC were also recorded for both treatment groups
throughout the study. There were no signi¢cant di¡er-
ences in lung function measurements between treat-
ments.
A reduction of approximately 30% in ACQ scores in
both treatment groups was sustained during the 12-
month treatment period (Fig. 3). Both treatments re-
sulted in similar improvements in all four domains and
overall MiniAQLQ scores throughout the study (Fig. 4).
No statistically signi¢cant di¡erences between treat-
ments in 9- and 12-month ACQ or MiniAQLQ scores
were identi¢ed.DISCUSSION
This study demonstrates that long-term treatment with
budesonide/formoterol from a single inhaler iswell toler-
ated.Over a12-month treatment period, there were no
clinically important di¡erences between the single inha-
ler product and budesonide plus formoterol adminis-
tered via separate inhalers in AEs, vital signs, ECG or
laboratory measurements (including morning serum
cortisol). As the included patients were using di¡erent
doses of IGCS, measurements of baseline cortisol values
were of limited value for determining the e¡ects of the
two studied treatment regimens. After 9 months of
treatment, less than 3% of the patients hadmorning ser-
um cortisol values below the reference range, indicating
limited suppression e¡ects. Budesonide/formoterol was
also at least as e¡ective as budesonide plus formoterol
in improving lung function, asthma control and health-
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706 RESPIRATORYMEDICINErelatedqualityof life throughout the12-month studyper-
iod.
Importantly, signi¢cantly fewer patients withdrew
from treatment with budesonide/formoterol compared
with budesonide plus formoterol (P=0.008), con¢rming
the trend seen in the 6-month study (13). As a long-term
open-label study, this study is likely to more closely re-
£ect real-life clinical experience than short-term studies,
where patients tend to bemoremotivated than those in
general practice. These results suggest that long-term
adherence to treatment may be improved with budeso-
nide/formoterol single inhaler compared with budeso-
nide plus formoterol via separate inhalers, whichmay be
due to the greater simplicity and convenience of single-
inhaler therapy compared with dual-inhaler therapy. In-
creasing the number of treatments (16), and the fre-
quency of dosing (17) reduces the likelihood of
adherence to treatment in asthma, resulting in increasedmorbidity and treatment costs. Health-economic analy-
sis of data from the current study has demonstrated that
long-term treatment with budesonide/formoterol is in-
deed associatedwith a signi¢cantly lower average annual
cost of treatment compared with budesonide plus for-
moterol (8914 SEKvs.10509 SEK, P=0.0004) (18).
Short-term studies have demonstrated that the com-
bination of formoterol and budesonide in a single inhaler
provides e¡ective asthma control in adults and children
with asthma not controlled on budesonide alone (10^12).
Although concerns have been expressed that the long-
term use of formoterol or salmeterol, when used to-
gether with IGCS, might mask the development or per-
sistence of airway in£ammation (19,20), these concerns
do not appear to be re£ected in clinical practice. Studies
have shown no increase in markers of in£ammation on
treatmentwith formoterol andbudesonide (20,21),while
the 1-year Formoterol And Corticosteroid Establishing
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halers In the Management of Asthma (OPTIMA) studies
demonstrated that addition of formoterol to budesonide
signi¢cantly reduced the incidence of both mild and se-
vere exacerbations (3,4). In our study, there were no in-
dications of any worseningof symptomswith formoterol
and budesonide treatment and the bene¢cial e¡ect of
treatment on lung function, asthma control and health-
related quality of life was maintained throughout the12-
month study period.
CONCLUSIONS
This study demonstrated that budesonide/formoterol in
a single inhaler and budesonide plus formoterol via sepa-rate inhalers were similarly well tolerated over a 12-
month period. Furthermore, improved lung function,
asthma control and health-related quality of life were
maintainedwithout indication of any worsening in symp-
toms.
The greater simplicity and convenience of single-inha-
ler budesonide/formoterol therapy may result in better
adherence to treatment, indicatedby fewerwithdrawals,
than budesonide plus formoterol via separate inhalers.
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